To take advantage of the latest targeted therapies in gastroesophageal cancer, physicians needed to identify patients who will benefit, but biomarker testing in this population continued to lag.
A single-center study found that using B-cell levels to determine when to infuse rituximab reduced relapses in patients antineutrophil cytoplasmic antibody vasculitis.